Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2013-004014-17
    Sponsor's Protocol Code Number:FIL_GA101_DHAP
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2014-06-04
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2013-004014-17
    A.3Full title of the trial
    Phase II study with Ga101-DHAP as induction therapy in relapsed/refractory
    Diffuse Large B-cell Lymphoma (DLBCL) patients before High-Dose
    chemotherapy BEAM with autologous stem cell transplantation (ASCT).
    Studio di Fase II con Ga101-DHAP in pazienti affetti da linfoma diffuso a grandi cellule B (DLBCL) ricaduti/refrattari, come terapia di induzione prima della chemioterapia ad alte dosi BEAM seguita da trapianto autologo di cellule staminali (ASCT). (Studio GIOTTO)
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Phase II study with Ga101-DHAP as induction therapy in relapsed/refractory
    Diffuse Large B-cell Lymphoma (DLBCL) patients before High-Dose
    chemotherapy BEAM with autologous stem cell transplantation (ASCT).
    Studio di Fase II con Ga101-DHAP in pazienti affetti da linfoma diffuso a grandi cellule B (DLBCL) ricaduti/refrattari, come terapia di induzione prima della chemioterapia ad alte dosi BEAM seguita da trapianto autologo di cellule staminali (ASCT). (Studio GIOTTO)
    A.3.2Name or abbreviated title of the trial where available
    FIL_GA101_DHAP
    FIL_GA101_DHAP
    A.4.1Sponsor's protocol code numberFIL_GA101_DHAP
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorFondazione Italiana Linfomi ONLUS
    B.1.3.4CountryItaly
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportFondazione Italiana Linfomi ONLUS
    B.4.2CountryItaly
    B.4.1Name of organisation providing supportRoche S.p.A.
    B.4.2CountryItaly
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationFondazione Italiana Linfomi ONLUS
    B.5.2Functional name of contact pointSegreteria FIL ONLUS
    B.5.3 Address:
    B.5.3.1Street AddressVia Venezia, 16
    B.5.3.2Town/ cityAlessandria
    B.5.3.3Post code15121
    B.5.3.4CountryItaly
    B.5.4Telephone number00390131206132
    B.5.5Fax number00390131263455
    B.5.6E-mailsegreteria@filinf.it
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameRO5072759
    D.3.2Product code GA101
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNOBINUTUZUMAB
    D.3.9.1CAS number 949142-50-1
    D.3.9.2Current sponsor codeGA101DHAP
    D.3.9.3Other descriptive nameOBINUTUZUMAB
    D.3.9.4EV Substance CodeSUB32751
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number25
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product type Glyco-engineered and humanized monoclonal antibody.
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Young patients with DLBCL who failed or relapsed after one previous chemotherapy regimen.
    Pazienti giovani con DLBCL recidivati o refrattari dopo una precedente linea di chemioterapia.
    E.1.1.1Medical condition in easily understood language
    Young patients with DLBCL who failed or relapsed after one previous chemotherapy regimen.
    Pazienti giovani con DLBCL recidivati o refrattari dopo una precedente linea di chemioterapia.
    E.1.1.2Therapeutic area Diseases [C] - Blood and lymphatic diseases [C15]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 17.0
    E.1.2Level HLT
    E.1.2Classification code 10012819
    E.1.2Term Diffuse large B-cell lymphomas
    E.1.2System Organ Class 100000004851
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Aim of this trial is to assess the efficacy of new anti-CD20 antibody (GA101) in association with DHAP as induction therapy before high dose chemotherapy BEAM with ASCT in patients with relapsed/refractory DLBCL.
    Primary objective is to assess whether the treatment achieves an absolute increase of the CR proportion of at least 20% (from 30% to 50%) with respect to the standard treatment.
    Lo scopo di questo studio è quello di valutare l'efficacia del nuovo anticorpo CD-20 (GA101) in associazione con DHAP come terapia di induzione prima di una chemioterapia ad alte dosi BEAM con ASCT in pazienti con linfoma DLBCL recidivato/refrattario. L'obiettivo primario è valutare se il trattamento raggiunge un incremento assoluto del RC nella proporzione di almeno il 20% (da 30 a 50%) rispetto al trattamento standard.
    E.2.2Secondary objectives of the trial
    • Overall Response Rate (ORR) prior to consolidation with BEAM and ASCT
    • Progression free survival (PFS)
    • Overall Survival (OS)
    • Feasibility and toxicity
    • The hematopoietic cell mobilization
    • The rate of patients actually proceeding to ASCT.
    Risposta globale (ORR) prima del consoliamento con BEAM e ASCT
    Sopravvivenza libera da progressione: PFS
    Sopravvivenza globale: OS
    Fattibilità e tossicità
    Mobilizzazione cellule emopoietiche
    Tasso di pazienti da avviare al ASCT
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. 18≥ Age < 65
    2. Relapsed/refractory disease after receiving one line of standard R-CHOP like chemotherapy
    3. Diffuse Large B-cell Lymphoma at relapse. Patient has to be re-biopsied prior study entry. This is particularly recommended if relapse is over 1 year from previous complete remission. If this is harmful for the patient, the patient can be enrolled if archivial tumor sample and block from first diagnosis are available.
    4. Measurable and/or evaluable disease
    5. Any Ann Arbor stage and IPI group at relapse
    6. Performance status < 2 according to ECOG scale unless due to lymphoma
    7. No Central Nervous System (CNS) disease (meningeal and/or brain involvement by lymphoma)
    8. Adequate haematological counts: ANC > 1.5 x 109/L, Hgb > 10.5 g/dl (transfusion independent), Platelet count > 75 x 109/L (transfusion independent), with the exception of cytopenia due to lymphoma bone marrow involvement
    9. Normal liver function (ALP, AST, ALT, GGT, conjugated bilirubin total < 2 x ULN) if not related to lymphoma
    10. Normal kidney function (creatinine clearance > 45 ml/min)
    11. Cardiac ejection fraction > 50% (MUGA scan or echocardiography)
    12. Normal lung function
    13. Absence of active infections
    14. Non peripheral neuropathy or active neurological non neoplastic disease of CNS
    15. Non major surgical intervention prior 3 months to randomization if not due to lymphoma and/or not other disease life-threatening that can compromise chemotherapy treatment
    16. Disease free of prior malignancies other than lymphoma for > 3 years with exception of currently treated squamous cell and basal cell carcinoma of the skin or carcinoma in situ of the cervix or breast
    17. Life expectancy > 6 months
    18. No psychiatric illness that precludes understanding concepts of the trial or signing informed consent
    19. Written informed consent
    20. Women must be:
    - postmenopausal for at least 1 year (must not have had a natural menses for at least 12 months)
    - surgically sterile (have had a hysterectomy or bilateral oophorectomy, tubal ligation, or otherwise be incapable of pregnancy),
    - abstinent (at the discretion of the investigator/per local regulations), or
    - if sexually active, be practicing a highly effective method of birth control (eg, prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double-barrier method (eg, condoms, diaphragm, or cervical cap, with spermicidal foam, cream, or gel, male partner sterilization) as local regulations permit, before entry, and must agree to continue to use the same method of contraception throughout the study. They must also be prepared to continue birth control measures for at least 12 months after terminating treatment.
    21. Women of childbearing potential must have a negative serum or urine beta-human chorionic gonadotropin (beta-hCG) pregnancy test at screening
    22. Men must agree to use an acceptable method of contraception (for themselves or female partners as listed above) for the duration of the study. Men must agree to use a double barrier method of birth control and to not donate sperm during the study and for 3 months after receiving the last dose of study drug.
    1. 18≥ Età < 65
    2. Linfoma diffuso a grandi cellule B refrettario o recidivato dopo un qualsiasi trattamento di prima linea.
    3. Linfoma diffuso a grandi cellule alla ricaduta. Il paziente deve aver ripetuto la biopsia prima di entrare nello studio. Questa è particolarmente raccomandata se la recidiva risale a più di un anno prima della remissione completa. Se questa costituisce un danno per il paziente, è possibile arruolare se il campione del tumore o il blocchetto della prima diagnosi sono disponibili.
    4. Malattia misurabile e/o valutabile.
    5. Qualsiasi stadio di Ann Arbor o gruppo IPI alla recidiva
    6. ECOG Performance status < 2 a meno che non sia dovuto al linfoma
    7. Assenza di interessamento del sistema nervoso centrale (SNC) (coinvolgimento del linfoma cerebrale/meningeo)
    8. Valori ematologici adeguati: neutrofili > 1.5 x 109/L, emoglobina > 10.5 g/dl (indipendente dalla trasfusione), conta piastrinica > 75 x 109/L (indipendente dalla trasfusione), con eccezione della pancitopenia dovuta a conivolgimento midollare da parte del linfoma
    9. Normale funzionalità epatica (ALP, AST, ALT, GGT, bilirubina totale < 2 x ULN) se non dovuta al linfoma
    10. Normale funzionalità renale (clearance della creatinina > 45 ml/min)
    11. Frazione di eiezione > 50% (MUGA scan o ecocardiografia)
    12. Normale funzionalità polmonare
    13. Assenza di infezioni opportunistiche
    14. Assenza di neuropatia periferica o malattia neurologica attiva non neoplastica del SNC
    15. Nessun intervento chirurgico entro tre mesi dalla randomizzazione a meno che non sia dovuta al linfoma e/o ad altre patologie per pericolo di vita che possano compromettere il trattamento chemioterapico
    16. Assenza di malattie neoplastiche nei precedenti tre anni ad eccezione del linfoma o carcinoma squamocellulare della cute o carcinoma in sito di cervice o mammella
    17. Aspettativa di vita > 6 mesi
    18. Assenza di malattie psichiatriche che precludano la possibilità di comprendere lo studio o firmare un il consenso informato
    19. Consenso informato scritto
    20. Le donne devono essere:
    - in menopausa da almeno 1 anno (assenza di una mestruazione naturale per almeno 12 mesi)
    - Chirurgicamente sterili (hanno avuto una isterectomia o ovariectomia bilaterale, legatura delle tube, o altrimenti impossibilitate ad una gravidanza),
    - Astinenti (a discrezione dello sperimentatore / per le normative locali), o
    - Se sessualmente attive, praticanti un metodo altamente efficace di controllo delle nascite come ad esempio, contraccettivi orali, iniezioni contraccettive, cerotto contraccettivo, dispositivo intrauterino, metodo a doppia barriera (ad esempio, preservativi, diaframma o cappuccio cervicale, con schiuma, crema, o gel spermicida, sterilizzazione del partner maschile), come ammesso dalle normative locali, prima dell’arruolamento, e devono accettare di continuare a utilizzare lo stesso metodo di contraccezione durante lo studio. Essi devono anche essere pronte a continuare le misure di contraccezione per almeno 12 mesi dopo la cessazione del trattamento.
    21. Le donne potenzialmente fertili devono avere un siero negativo o lo screening test di gravidanza della gonadotropina corionica umana (beta-hCG) negativa nelle urine.
    22. Gli uomini devono acconsentire all’utilizzo di un metodo contraccettivo adeguato (per sé o partner femminili come elencato sopra) per tutta la durata dello studio. Gli uomini devono accettare di utilizzare un doppio metodo di barriera di controllo delle nascite e non donare sperma durante lo studio e per 3 mesi dopo l'ultima dose del farmaco in studio.
    E.4Principal exclusion criteria
    1. Diagnosis of Lymphoblastic Lymphoma, Burkitt Lymphoma, Non Hodgkin Lymphoma CD20 negative, Mantle Cell Lymphoma, Follicular Lymphoma, Primary Mediastinal Lymphoma
    2. Age ≥ 65 years
    3. Patients ineligible to high-dose chemotherapy
    4. Performance status > 2 according to ECOG scale if not due to lymphoma
    5. Patients who previously received GA101 (obinutuzumab) are excluded.
    6. Patient has known or suspected hypersensitivity or intolerance to Rituximab
    7. Patient has received an experimental drug or used an experimental medical device within 4 weeks before the planned start of treatment. Concurrent participation in non-treatment studies is allowed, if it will not interfere with participation in this study.
    8. CNS disease (meningeal and/or brain involvement by lymphoma)
    9. History of clinically relevant liver or renal insufficiency; significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, rheumatologic, hematologic, psychiatric, or metabolic disturbances
    10. Positive test results for chronic hepatitis B infection (defined as positive HBsAg serology)
    Patients with occult or prior hepatitis B infection (defined as positive total hepatitis B core antibody and negative HBsAg) may be included if HBV DNA is undetectable. These patients must be willing to undergo monthly DNA testing.
    11. Positive test results for hepatitis C (HCV antibody serology testing)
    Patients positive for HCV antibody are eligible only if PCR is negative for HCV RNA.
    12. Known history of HIV seropositive status
    For patients with unknown HIV status, HIV testing will be performed at screening if required by local regulations.
    13. Uncontrolled diabetes (if receiving antidiabetic agents, subjects must be on a stable dose for at least 3 months before first dose of study drug
    14. Uncontrolled or severe cardiovascular disease including myocardial infarction within six months of enrollment, New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, clinically significant pericardial disease, or cardiac amyloidosis
    15. Cardiac ejection fraction < 45% (MUGA scan or echocardiography)
    16. Creatinine clearance < 45 ml/min
    17. Presence of major neurological disorders
    18. Active infection
    19. Major surgical intervention prior 3 months to randomization if not due to lymphoma and/or other disease life-threatening that can compromise chemotherapy treatment
    20. Prior malignancies other than lymphoma in the last 3 years with exception of currently treated squamous cell and basal cell carcinoma of the skin or carcinoma in situ of the cervix or breast
    21. Life expectancy < 6 months
    22. Any other coexisting medical or psychological condition that would preclude participation in the study or compromise ability to give informed consent.
    23. If female, the patient is pregnant or breast-feeding.
    1. Diagnosi di linfoma linfoblastico, Linfoma di Burkitt, Linfoma non-Hodgkin CD20 negativo, Linfoma mantellare, Linfoma follicolare, Linfoma primitivo del mediastino
    2. Età > 65 anni
    3. Paziente non elegibile per terapie ad alte dosi
    4. ECOG Performance status > 2 se non dovuto al linfoma
    5. Pazienti che hanno già ricevuto GA101 (obinutuzumab) sono esclusi
    6. Sospetta o nota ipersensibilità o intolleranza al Rituximab
    7. Avere ricevuto un farmaco sperimentale entro 4 settimane dall’inizio della terapia programmata. La concomitante partecipazione in studi non interventistici è permessa, se questo non comprometterà la partecipazione a questo studio.
    8. Malattia al SNC (coinvolgimento del linfoma cerebrale/meningeo).
    9. Storia di patologie clinicamente rilevanti a livello epatico o renale; cardiaco, vascolare, polmonare, gastrointestinale, endocrino, neurologico, reumatologico, ematologico, psichiatrico o metabolico.
    10. test positivo per l'infezione da epatite B cronica (HBsAg sierologica positiva). I pazienti con infezione da epatite B occulta o precedentemente infetti (positivi agli anticorpi totali dell'epatite B e HBsAg negativi) possono essere compresi se il DNA dell'HBV non è rilevabile. Questi pazienti devono essere disposti a sottoporsi al test del DNA mensilmente
    11. Risultati positivi all'EpatiteC (Test sierologico degli anticorpi HCV). I pazienti positivi per gli anticorpi HCV sono eleggibili solo se la PCR RNA HCV è negativa.
    12. HIV positività, HCV positività, HBV positività con l’eccezione dei pazienti HBVcAb +, HbsAg -, HBs Ab+/- e con HBV-DNA negativo
    13. Diabete scompensato (se trattati con agenti antidiabetici, i soggetti devono essere su una dose stabile per almeno 3 mesi prima della prima dose del farmaco in studio).
    14. Cardiopatia severa e scompensata: includendo infarto del miocardio entro sei mesi dall’arruolamento, angina instabile, classe NYHA III o IV, malattia pericardica clinicamente significativa, amiloidosi cardiaca
    15. Frazione di eiezione < 45% (MUGA scan o ecocardiografia)
    16. Clearance della creatinina < 45 ml/min
    17. Presenza di disturbi neurologici maggiori
    18. Infezioni opportunistiche attive
    19. Interventi chirurgici maggiori entro tre mesi dalla randomizzazione non dovuti al linfoma e/o ad altre patologie per pericolo di vita che possano compromettere il trattamento chemioterapico
    20. Precedenti malattie neoplastiche diverse dal linfoma nei precedenti tre anni ad eccezione del carcinoma squamocellulare della cute o carcinoma in sito di cervice o mammella
    21. Aspettativa di vita < 6 mesi
    22. Ogni altra condizione medica o psicologica che comprometta la possibilità di partecipare allo studio o comprometta la capacità di firmare il consenso informato.
    23. Se donna, la gravidanza o l’allattamento al seno.
    E.5 End points
    E.5.1Primary end point(s)
    The complete response rate (CR) evaluated by PET scan after four cycles of GA101-DHAP before ASCT according to Cheson criteria.
    Il tasso di risposta completa (RC) valutata in base alla PET dopo quattro cicli di GA101-DHAP prima di ASCT secondo i criteri di Cheson.
    E.5.1.1Timepoint(s) of evaluation of this end point
    After 4 cycles of treatment with GA101-DHAP.
    Dopo 4 cicli di terapia con GA101-DAHP
    E.5.2Secondary end point(s)
    1- Overall response rate (ORR): a patient is defined as a responder if she/he has a complete or partial response, evaluated by PET/TC, after four cycles of GA101-DHAP
    2- Progression free survival (PFS): measured from the date of starting salvage therapy to the date of disease progression, relapse or death from any cause. Responding patients and patients who are lost to follow up will be surveyed at their last assessment date.
    3- OS: measured from the date of starting salvage therapy to the date of death from any cause. Patients alive at the time of the final analysis will be surveyed at the date of the last contact. For both PFS and OS minimum follow up time required for all patients will be 2 years.
    4- Toxicity: severe, life-threatening, fatal (grade 3, 4 and 5) and/or serious adverse events are defined according to “Common Terminology Criteria for Adverse Events” (CTCAE), version 4.0.
    5- Mobilizing potential: amount of CD34 + stem cell collected /Kg
    6- Feasibility: proportion of randomized patients successfully completing ASCT
    1- tasso di risposta globale (ORR): un paziente è definito come responsivo se ha una risposta completa o parziale, valutati da PET / TC, dopo quattro cicli di GA101-DHAP
    • la sopravvivenza libera da progressione (PFS): misurata a partire dalla data di inizio terapia di salvataggio fino alla data di progressione della malattia, recidiva o di morte per qualsiasi causa. I pazienti responsivi ed i pazienti che si sono persi al follow-up saranno censiti alla loro ultima data di valutazione.
    • OS: misurata a partire dalla data di inizio terapia di salvataggio fino alla data di morte per qualsiasi causa. I pazienti vivi al momento dell'ultima analisi saranno censiti alla data dell'ultimo contatto. Sia per la PFS che per l'OS è richiesto un tempo minimo di follow up di tutti i pazienti di 2 anni.
    • Tossicità: le tossicità severe, il pericolo per la vita, gli eventi fatali (grado 3, 4 e 5) e / o gravi sono definiti in base ai "Criteri Comuni di Terminologia per gli Eventi Avversi" (CTCAE), versione 4.0.
    •Potenziale mobilizzazione: quantità di CD34 + cellule staminali raccolte / Kg
    • Fattibilità: proporzione di pazienti randomizzati che hanno completato con successo l'ASCT
    E.5.2.1Timepoint(s) of evaluation of this end point
    2 years of FU
    2 anni di FU
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned30
    E.8.5The trial involves multiple Member States No
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years
    E.8.9.1In the Member State concerned months36
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial months36
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 78
    F.1.3Elderly (>=65 years) No
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state78
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None.
    Nessuna indicazione.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2014-08-04
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2014-06-26
    P. End of Trial
    P.End of Trial StatusCompleted
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 21:05:06 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA